PubRank

Licia Rivoltini

Author PubWeight™ 112.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007 6.68
2 New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009 4.15
3 High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009 3.10
4 Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002 3.02
5 Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007 2.80
6 Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006 2.77
7 Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006 2.61
8 Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002 2.57
9 Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011 2.44
10 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
11 Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012 2.03
12 Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004 2.02
13 Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005 2.00
14 Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2011 1.94
15 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
16 pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010 1.58
17 Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002 1.56
18 NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res 2007 1.50
19 Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 2009 1.48
20 Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003 1.46
21 Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 2012 1.46
22 Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012 1.45
23 Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer 2012 1.45
24 Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res 2012 1.41
25 LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J Immunol 2010 1.37
26 Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 2010 1.35
27 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
28 Immune surveillance properties of human NK cell-derived exosomes. J Immunol 2012 1.26
29 Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 2011 1.26
30 Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res 2005 1.24
31 IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004 1.22
32 Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother 2003 1.20
33 A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 2013 1.17
34 A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2005 1.17
35 Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003 1.17
36 Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012 1.15
37 Proton dynamics in cancer. J Transl Med 2010 1.14
38 More insights into the immunosuppressive potential of tumor exosomes. J Transl Med 2008 1.14
39 CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008 1.14
40 Melanoma immunology: past, present and future. Curr Opin Oncol 2007 1.07
41 The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003 1.06
42 Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 2007 1.06
43 Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006 1.06
44 Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol 2005 1.05
45 Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2010 1.03
46 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
47 DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Int J Cancer 2005 1.01
48 Immunotherapy of melanoma. Semin Cancer Biol 2003 1.01
49 Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol 2004 1.01
50 Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity. Cancer Res 2006 0.95
51 Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 2009 0.94
52 T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun 2002 0.94
53 Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003 0.93
54 Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007 0.93
55 T cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J Transl Med 2005 0.92
56 Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses. J Immunol 2008 0.92
57 Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol 2003 0.91
58 Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004 0.90
59 Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 2014 0.88
60 Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol Immunother 2008 0.87
61 Heat shock proteins and their use as anticancer vaccines. Clin Cancer Res 2004 0.87
62 Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003 0.86
63 Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells. J Immunol 2009 0.85
64 Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007 0.85
65 Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2006 0.85
66 The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors. Oncoimmunology 2013 0.84
67 Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res 2005 0.84
68 Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003 0.84
69 Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation. J Immunol 2008 0.83
70 Heat shock proteins gp96 as immunogens in cancer patients. Int J Hyperthermia 2006 0.83
71 Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother 2013 0.82
72 HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. J Immunother 2010 0.82
73 Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res 2003 0.82
74 Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies. Cancer Immunol Immunother 2014 0.80
75 Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. Eur J Cancer 2005 0.80
76 A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. BMC Med Genet 2014 0.79
77 Chemokine receptor 7, a new player in regulating apoptosis of CD8+ T cells in cancer patients. Clin Cancer Res 2005 0.79
78 Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. J Transl Med 2013 0.79
79 Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. Clin Cancer Res 2008 0.79
80 Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. Carcinogenesis 2012 0.78
81 Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment. Expert Rev Mol Diagn 2014 0.78
82 Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther 2006 0.77
83 Spheres of influence in cancer stem cell biology. J Invest Dermatol 2010 0.76
84 Don't run before you can walk. Nat Rev Urol 2012 0.75
85 Exploiting liver immunity for the prevention of hepatic metastases. J Hepatol 2010 0.75
86 Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients. Methods Mol Biol 2014 0.75
87 Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. Int J Cancer 2009 0.75